600566 济川药业
已收盘 07-10 15:00:00
资讯
新帖
简况
济川药业最新公告:主要产品小儿豉翘清热颗粒新纳入国家基药目录
证券之星 · 07-09 17:50
济川药业最新公告:主要产品小儿豉翘清热颗粒新纳入国家基药目录
每周股票复盘:济川药业(600566)股价跌幅偏离值达7%
证券之星 · 07-05
每周股票复盘:济川药业(600566)股价跌幅偏离值达7%
济川药业(600566)披露2022年激励计划2026年第二季度自主行权结果暨股本变动公告,7月1日股价上涨1.22%
证券之星 · 07-01
济川药业(600566)披露2022年激励计划2026年第二季度自主行权结果暨股本变动公告,7月1日股价上涨1.22%
6月30日济川药业(600566)龙虎榜数据:机构净卖出5859.28万元
证券之星 · 06-30
6月30日济川药业(600566)龙虎榜数据:机构净卖出5859.28万元
每周股票复盘:济川药业(600566)每股派息1.74元
证券之星 · 06-28
每周股票复盘:济川药业(600566)每股派息1.74元
济川药业(600566)披露调整2022年股票期权行权价格公告,6月23日股价上涨1.44%
证券之星 · 06-23
济川药业(600566)披露调整2022年股票期权行权价格公告,6月23日股价上涨1.44%
济川药业(600566.SH):合作产品玛硒洛沙韦片新适应症获得药品注册证书
智通财经 · 06-08
济川药业(600566.SH):合作产品玛硒洛沙韦片新适应症获得药品注册证书
每周股票复盘:济川药业(600566)员工持股计划完成非交易过户
证券之星 · 06-07
每周股票复盘:济川药业(600566)员工持股计划完成非交易过户
济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,6月1日股价上涨0.73%
证券之星 · 06-01
济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,6月1日股价上涨0.73%
每周股票复盘:济川药业(600566)将召开2025年年度业绩说明会
证券之星 · 05-31
每周股票复盘:济川药业(600566)将召开2025年年度业绩说明会
济川药业(600566)披露2022年激励计划首次授予股票期权限制行权期间公告,5月27日股价下跌1.96%
证券之星 · 05-27
济川药业(600566)披露2022年激励计划首次授予股票期权限制行权期间公告,5月27日股价下跌1.96%
济川药业(600566)披露2024年员工持股计划第二个锁定期届满提示性公告,5月25日股价上涨3.04%
证券之星 · 05-25
济川药业(600566)披露2024年员工持股计划第二个锁定期届满提示性公告,5月25日股价上涨3.04%
每周股票复盘:济川药业(600566)蒲地蓝口服液获中药保护品种
证券之星 · 05-24
每周股票复盘:济川药业(600566)蒲地蓝口服液获中药保护品种
济川药业(600566)披露2025年年度股东会决议公告,5月18日股价下跌2.05%
证券之星 · 05-18
济川药业(600566)披露2025年年度股东会决议公告,5月18日股价下跌2.05%
济川药业(600566.SH):蒲地蓝消炎口服液获批国家中药保护品种
智通财经 · 05-17
济川药业(600566.SH):蒲地蓝消炎口服液获批国家中药保护品种
每周股票复盘:济川药业(600566)健胃消食口服液拟中选集采
证券之星 · 05-10
每周股票复盘:济川药业(600566)健胃消食口服液拟中选集采
济川药业(600566)披露回购股份进展公告,5月7日股价上涨1.79%
证券之星 · 05-07
济川药业(600566)披露回购股份进展公告,5月7日股价上涨1.79%
券商重仓路径曝光:去年单股最高持仓超百亿,一季度新进百余股
第一财经 · 05-07
券商重仓路径曝光:去年单股最高持仓超百亿,一季度新进百余股
济川药业最新公告:健胃消食口服液拟中选全国中成药集中带量采购
证券之星 · 05-07
济川药业最新公告:健胃消食口服液拟中选全国中成药集中带量采购
每周股票复盘:济川药业(600566)股东户数降11.25%,一季报营收下滑20.84%
证券之星 · 04-26
每周股票复盘:济川药业(600566)股东户数降11.25%,一季报营收下滑20.84%
加载更多
公司概况
公司名称:
湖北济川药业股份有限公司
所属行业:
医药制造业
上市日期:
2001-08-22
主营业务:
湖北济川药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是小儿豉翘清热颗粒、糖浆剂型、蒲地蓝消炎口服液、黄龙止咳颗粒、三拗片、健胃消食口服液、硫酸镁钠钾口服用浓溶液、甘海胃康胶囊、妇炎舒胶囊、蛋白琥珀酸铁口服溶液。2025年7月,“2024年度中国医药工业主营业务收入前100位企业”名单在第42届全国医药工业信息年会上发布,济川控股位列榜单第42位。
发行价格:
7.80
{"stockData":{"symbol":"600566","market":"SH","secType":"STK","nameCN":"济川药业","latestPrice":23.96,"timestamp":1783666800000,"preClose":24.1,"halted":0,"volume":6180996,"delay":0,"changeRate":-0.0058,"floatShares":919000000,"shares":922000000,"eps":1.8853,"marketStatus":"已收盘","change":-0.14,"latestTime":"07-10 15:00:00","open":23.9,"high":24.3,"low":23.5,"amount":148000000,"amplitude":0.0332,"askPrice":23.96,"askSize":21,"bidPrice":23.95,"bidSize":7,"shortable":0,"etf":0,"ttmEps":1.8853,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783906200000},"marketStatusCode":5,"adr":0,"adjPreClose":24.1,"symbolType":"stock","openAndCloseTimeList":[[1783647000000,1783654200000],[1783659600000,1783666800000]],"highLimit":26.51,"lowLimit":21.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":921731260,"isCdr":false,"pbRate":1.47,"roa":"--","peRate":12.708853,"roe":"2.7%","epsLYR":1.93,"committee":0.213115,"marketValue":22085000000,"turnoverRate":0.0067,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2026-07-13。","floatMarketCap":22010000000},"requestUrl":"/m/hq/s/600566","defaultTab":"news","newsList":[{"id":"2650792842","title":"济川药业最新公告:主要产品小儿豉翘清热颗粒新纳入国家基药目录","url":"https://stock-news.laohu8.com/highlight/detail?id=2650792842","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650792842?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:50","pubTimestamp":1783590651,"startTime":"0","endTime":"0","summary":"济川药业(600566.SH)公告称,公司全资子公司济川药业集团有限公司的主要产品小儿豉翘清热颗粒新纳入《国家基本药物目录(2026年版)》。该产品为独家品种,2025年度销售收入15.19亿元,占公司营收24.43%;2026年第一季度销售收入2.64亿元,占营收21.87%。本次纳入将有利于产品在基层医疗市场的规模扩大,但对当期经营业绩无重大影响。以上内容为证券之星据公开信息整理,仅供参考不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070900032190.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0028","600566","BK0012","BK0187","BK0201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649947016","title":"每周股票复盘:济川药业(600566)股价跌幅偏离值达7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2649947016","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649947016?lang=zh_cn&edition=full","pubTime":"2026-07-05 03:05","pubTimestamp":1783191913,"startTime":"0","endTime":"0","summary":"截至2026年7月3日收盘,济川药业报收于22.47元,较上周的25.4元下跌11.54%。本周,济川药业6月29日盘中最高价报26.4元。济川药业当前最新总市值207.11亿元,在中药板块市值排名12/66,在两市A股市值排名1050/5203。本周关注点来自交易信息汇总:济川药业因日收盘价格跌幅偏离值达到7%登上龙虎榜。公司公告汇总湖北济川药业股份有限公司发布2022年限制性股票与股票期权激励计划2026年第二季度自主行权结果暨股本变动公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070500000949.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600566","BK0239","BK0077","BK0012","BK0188","BK0187","BK0028","BK0201"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648541870","title":"济川药业(600566)披露2022年激励计划2026年第二季度自主行权结果暨股本变动公告,7月1日股价上涨1.22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2648541870","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648541870?lang=zh_cn&edition=full","pubTime":"2026-07-01 22:24","pubTimestamp":1782915859,"startTime":"0","endTime":"0","summary":"截至2026年7月1日收盘,济川药业报收于22.46元,较前一交易日上涨1.22%,最新总市值为207.02亿元。近日,湖北济川药业股份有限公司发布《关于2022年限制性股票与股票期权激励计划2026年第二季度自主行权结果暨股本变动公告》。2026年第二季度行权并完成过户登记的股份为69,000股,截至该季度末累计行权并完成过户登记1,242,400股。2026年第二季度共有5名激励对象参与行权,累计52人完成行权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100043457.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0077","BK0028","BK0188","BK0239","600566","BK0201","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647894534","title":"6月30日济川药业(600566)龙虎榜数据:机构净卖出5859.28万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2647894534","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647894534?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:47","pubTimestamp":1782812856,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2026年6月30日公布的交易公开信息显示,济川药业因有价格涨跌幅限制的日收盘价格跌幅偏离值达到7%的前五只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年6月30日收盘,XD济川药报收于22.19元,下跌9.98%,换手率1.68%,成交量15.48万手,成交额3.48亿元。从龙虎榜公布的当日买卖数据来看,机构合计净卖出5859.28万元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000033047.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0077","BK0201","BK0012","BK0188","BK0239","600566","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646892315","title":"每周股票复盘:济川药业(600566)每股派息1.74元","url":"https://stock-news.laohu8.com/highlight/detail?id=2646892315","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2646892315?lang=zh_cn&edition=full","pubTime":"2026-06-28 03:04","pubTimestamp":1782587053,"startTime":"0","endTime":"0","summary":"截至2026年6月26日收盘,济川药业报收于25.4元,较上周的25.91元下跌1.97%。本周,济川药业6月24日盘中最高价报27.49元。本周关注点公司公告汇总:济川药业2025年年度权益分派实施,每股现金红利1.74元(含税)。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062800000867.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0028","BK0201","BK0188","BK0239","BK0077","BK0187","600566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645527832","title":"济川药业(600566)披露调整2022年股票期权行权价格公告,6月23日股价上涨1.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2645527832","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645527832?lang=zh_cn&edition=full","pubTime":"2026-06-23 22:14","pubTimestamp":1782224075,"startTime":"0","endTime":"0","summary":"截至2026年6月23日收盘,济川药业报收于26.11元,较前一交易日上涨1.44%,最新总市值为240.66亿元。近日,湖北济川药业股份有限公司召开第十一届董事会第二次会议,审议通过了关于调整2022年限制性股票与股票期权激励计划首次授予股票期权行权价格的议案。因公司实施2025年度利润分配,每股派发现金红利1.74元(含税),根据激励计划相关规定,对股票期权行权价格进行调整,调整后的首次授予股票期权行权价格为19元/份。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062300042407.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0077","BK0028","BK0188","BK0239","600566","BK0201","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641483519","title":"济川药业(600566.SH):合作产品玛硒洛沙韦片新适应症获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2641483519","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641483519?lang=zh_cn&edition=full","pubTime":"2026-06-08 17:54","pubTimestamp":1780912497,"startTime":"0","endTime":"0","summary":"智通财经APP讯,济川药业(600566.SH)发布公告,近日,公司全资子公司济川药业集团有限公司与征祥医药(南京)集团股份有限公司(简称“征祥医药”)合作的玛硒洛沙韦片收到国家药品监督管理局核准签发的《药品注册证书》。该药品新适应症获批,用于既往健康的12岁及以上青少年单纯性甲型和乙型流感患者的治疗。据悉,玛硒洛沙韦片是征祥医药申报的1类新药,是新一代聚合酶酸性蛋白(PA)核酸内切酶抑制剂,具有广谱抗流感病毒的特性。此次获批的适应症是该药在国内获批的第二个适应症。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1451468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"济川药业(600566.SH):合作产品玛硒洛沙韦片新适应症获得药品注册证书","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600566","BK0077","BK0028","BK0188","BK0201","BK0239","BK0012","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641127512","title":"每周股票复盘:济川药业(600566)员工持股计划完成非交易过户","url":"https://stock-news.laohu8.com/highlight/detail?id=2641127512","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641127512?lang=zh_cn&edition=full","pubTime":"2026-06-07 02:20","pubTimestamp":1780770019,"startTime":"0","endTime":"0","summary":"截至2026年6月5日收盘,济川药业报收于27.99元,较上周的27.53元上涨1.67%。公司公告汇总湖北济川药业股份有限公司于2026年5月29日将484,058股A股普通股股票以非交易过户方式过户至2026年员工持股计划证券账户,过户价格为27.46元/股,占公司总股本的0.05%。管理委员会任期与员工持股计划存续期一致。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060700000660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0201","BK0028","600566","BK0012","BK0077","BK0187","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640895065","title":"济川药业(600566)披露以集中竞价交易方式回购股份的进展公告,6月1日股价上涨0.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640895065","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640895065?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:28","pubTimestamp":1780324097,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘,济川药业报收于27.73元,较前一交易日上涨0.73%,最新总市值为255.58亿元。近日,湖北济川药业股份有限公司发布《关于以集中竞价交易方式回购股份的进展公告》。公告显示,公司于2025年11月24日召开董事会,审议通过以集中竞价交易方式回购公司股份的方案,回购资金总额为2,500万元至5,000万元,用于员工持股计划或股权激励,回购价格不超过38元/股,实施期限为董事会审议通过后12个月内。上述回购符合相关规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100041149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","600566","BK0239","BK0201","BK0188","BK0028","BK0187","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639604452","title":"每周股票复盘:济川药业(600566)将召开2025年年度业绩说明会","url":"https://stock-news.laohu8.com/highlight/detail?id=2639604452","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639604452?lang=zh_cn&edition=full","pubTime":"2026-05-31 03:47","pubTimestamp":1780170430,"startTime":"0","endTime":"0","summary":"截至2026年5月29日收盘,济川药业报收于27.53元,较上周的28.0元下跌1.68%。公司公告汇总湖北济川药业股份有限公司将于2026年6月5日15:00-17:00通过上证路演中心召开2025年年度暨2026年第一季度业绩说明会,以视频录播和网络互动形式进行。湖北济川药业股份有限公司根据相关规定,结合2025年年度权益分派安排,对2022年限制性股票与股票期权激励计划首次授予股票期权的自主行权时间进行限制。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100001097.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0012","BK0188","600566","BK0077","BK0187","BK0201","BK0239","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638003686","title":"济川药业(600566)披露2022年激励计划首次授予股票期权限制行权期间公告,5月27日股价下跌1.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638003686","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638003686?lang=zh_cn&edition=full","pubTime":"2026-05-27 22:24","pubTimestamp":1779891860,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘,济川药业报收于27.97元,较前一交易日下跌1.96%,最新总市值为257.79亿元。公告显示,公司根据相关规定,结合2025年年度权益分派安排,对2022年限制性股票与股票期权激励计划首次授予股票期权的自主行权时间进行限制。本次限制行权期为2026年6月3日至2026年6月29日,期间全部激励对象将限制行权。首个行权期实际可行权期间为2025年10月15日至2026年9月7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052700046075.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0188","BK0028","600566","BK0012","BK0187","BK0201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638953469","title":"济川药业(600566)披露2024年员工持股计划第二个锁定期届满提示性公告,5月25日股价上涨3.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638953469","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638953469?lang=zh_cn&edition=full","pubTime":"2026-05-25 18:03","pubTimestamp":1779703400,"startTime":"0","endTime":"0","summary":"截至2026年5月25日收盘,济川药业报收于28.85元,较前一交易日上涨3.04%,最新总市值为265.9亿元。该股当日开盘27.92元,最高28.97元,最低27.86元,成交额达1.54亿元,换手率为0.59%。公告显示,公司2024年员工持股计划第二个锁定期于2026年5月23日届满,解锁日为2026年5月25日。锁定期届满后,管理委员会将根据市场情况择机出售可解锁股票,并依据个人绩效考核结果进行分配。持股计划严格遵守交易规则,禁止内幕交易和市场操纵行为。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052500025603.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0012","BK0239","600566","BK0188","BK0077","BK0187","BK0028"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637373706","title":"每周股票复盘:济川药业(600566)蒲地蓝口服液获中药保护品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2637373706","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637373706?lang=zh_cn&edition=full","pubTime":"2026-05-24 03:04","pubTimestamp":1779563053,"startTime":"0","endTime":"0","summary":"截至2026年5月22日收盘,济川药业报收于28.0元,较上周的28.26元下跌0.92%。本周,济川药业5月21日盘中最高价报28.99元。济川药业当前最新总市值258.07亿元,在中药板块市值排名9/66,在两市A股市值排名859/5206。本周关注点来自公司公告汇总:蒲地蓝消炎口服液获批首家中药二级保护品种,保护期七年。截至公告日,前期现金管理产品已全部赎回,本次投资不构成关联交易。公司2024年员工持股计划第二个锁定期已于2026年5月23日届满,解锁日为2026年5月25日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052400000819.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","BK0077","BK0012","BK0239","BK0201","BK0187","600566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636024112","title":"济川药业(600566)披露2025年年度股东会决议公告,5月18日股价下跌2.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636024112","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636024112?lang=zh_cn&edition=full","pubTime":"2026-05-18 18:06","pubTimestamp":1779098814,"startTime":"0","endTime":"0","summary":"截至2026年5月18日收盘,济川药业报收于27.68元,较前一交易日下跌2.05%,最新总市值为255.12亿元。该股当日开盘28.25元,最高28.34元,最低27.53元,成交额达1.74亿元,换手率为0.68%。近日,湖北济川药业股份有限公司发布《2025年年度股东会决议公告》。北京植德律师事务所对本次会议出具法律意见书,认为会议合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800028685.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0028","BK0239","BK0201","BK0012","BK0187","BK0077","600566"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636099249","title":"济川药业(600566.SH):蒲地蓝消炎口服液获批国家中药保护品种","url":"https://stock-news.laohu8.com/highlight/detail?id=2636099249","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636099249?lang=zh_cn&edition=full","pubTime":"2026-05-17 15:34","pubTimestamp":1779003244,"startTime":"0","endTime":"0","summary":"智通财经APP讯,济川药业(600566.SH)发布公告,近日,国家药品监督管理局网站发布《中药保护品种公告(第36号)(2026年第44号)》,批准公司全资子公司济川药业集团有限公司(简称“济川有限”)的蒲地蓝消炎口服液为首家中药二级保护品种。蒲地蓝消炎口服液是济川有限生产的独家剂型产品,具有清热解毒,消肿利咽的功效,适用于腮腺炎、咽炎、扁桃体炎及疖肿等上呼吸道感染性疾病治疗。该产品入选了包括《全国儿童呼吸道感染中医药防治方案》在内的三十余项指南及诊疗共识。本次蒲地蓝消炎口服液获批为国家中药二级保护品种,有利于该产品的知识产权保护。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442616.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"济川药业(600566.SH):蒲地蓝消炎口服液获批国家中药保护品种","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600566","BK0028","BK0012","BK0188","BK0077","BK0187","BK0201","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634146354","title":"每周股票复盘:济川药业(600566)健胃消食口服液拟中选集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2634146354","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634146354?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:26","pubTimestamp":1778351172,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总:健胃消食口服液拟中选全国中成药集采,2025年销售额占营收7.29%公司公告汇总:公司已累计回购股份93.47万股,支付金额2500.10万元公司公告汇总:2026年员工持股计划获律师所法律意见支持,股票来源为回购股份公司公告汇总:曹飞要约收购持续督导期内未发生重大调整或违规情形公司公告汇总湖北济川药业股份有限公司全资子公司济川药业集团有限公司产品健胃消食口服液拟中选全国中成药采购联盟集中带量采购。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000863.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0201","BK0077","BK0239","BK0187","600566","BK0012","BK0028","BK0188"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633260501","title":"济川药业(600566)披露回购股份进展公告,5月7日股价上涨1.79%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633260501","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633260501?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:56","pubTimestamp":1778165773,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘,济川药业报收于28.36元,较前一交易日上涨1.79%,最新总市值为261.38亿元。该股当日开盘27.86元,最高28.45元,最低27.82元,成交额达2.05亿元,换手率为0.79%。近日,湖北济川药业股份有限公司发布《关于以集中竞价交易方式回购股份的进展公告》。2026年4月未实施回购。上述回购符合相关规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041704.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0187","BK0028","BK0239","600566","BK0188","BK0012","BK0201","BK0077"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633128612","title":"券商重仓路径曝光:去年单股最高持仓超百亿,一季度新进百余股","url":"https://stock-news.laohu8.com/highlight/detail?id=2633128612","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633128612?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:42","pubTimestamp":1778157720,"startTime":"0","endTime":"0","summary":" “易中天”热度持续高涨,龙头券商也买进了前十大股东。 随着年报和一季报披露完毕,券商重仓路径浮现,在A股市场震荡上行中,哪些个股成为券商的“心头好”? 第一财经根据Choice数据统计,截至去年年底,券商现身近300家A股公司的前十大流通股股东名单,合计持股总市值超700亿元。其中,截至去年年底,中信证券对中信建投的持仓市值超过百亿元。 随着一季报披露收官,券商最新调仓换股路径同步曝光。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-07/doc-inhxatff4721846.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-07/doc-inhxatff4721846.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000670","BK0239","BK0012","300182","300532","BK0197","BK0187","600927","BK0108","BK0056","002714","LU1794554557.SGD","SGXZ49509284.SGD","000408","LU2399975544.HKD","BK0077","600919","LU1655091616.SGD","BK0195","SGXZ81163826.USD","BK0046","LU2495084118.USD","002252","LU0359202008.SGD","BK0109","BK0155","BK0201","603817","600863","LU1979443071.USD","LU1961090484.USD","301314","BK0125","300502","BK0132","BK0198","BK0127","601066","BK0182","BK0214","LU2778985437.USD","600566","02714","BK0189","BK0070","BK0252","002911","601658","BK0196","BK0015"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633112842","title":"济川药业最新公告:健胃消食口服液拟中选全国中成药集中带量采购","url":"https://stock-news.laohu8.com/highlight/detail?id=2633112842","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633112842?lang=zh_cn&edition=full","pubTime":"2026-05-07 17:49","pubTimestamp":1778147395,"startTime":"0","endTime":"0","summary":"济川药业(600566.SH)公告称,全资子公司济川有限参与了全国中成药采购联盟集中带量采购工作,根据拟中选结果公示,济川有限产品健胃消食口服液拟中选此次集中带量采购。上述拟中选产品健胃消食口服液2025年度销售收入约4.54亿元,占公司2025年度营业收入总额的比例为7.29%。以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700030025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0077","BK0201","BK0012","BK0188","BK0239","600566","BK0028","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630804511","title":"每周股票复盘:济川药业(600566)股东户数降11.25%,一季报营收下滑20.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2630804511","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630804511?lang=zh_cn&edition=full","pubTime":"2026-04-26 03:30","pubTimestamp":1777145431,"startTime":"0","endTime":"0","summary":"截至2026年4月24日收盘,济川药业报收于26.7元,较上周的24.9元上涨7.23%。本周,济川药业4月24日盘中最高价报26.85元。济川药业当前最新总市值246.08亿元,在中药板块市值排名9/66,在两市A股市值排名871/5200。业绩披露要点:2026年一季报主营收入12.07亿元,同比下降20.84%。股本股东变化截至2026年3月31日,公司股东户数为3.26万户,较2025年12月31日减少4136户,减幅11.25%。因8名激励对象离职,注销股票期权33.85万份,回购注销限制性股票33.85万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042600001423.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["600566"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1783727069814,"stockEarnings":[{"period":"1week","weight":0.0663},{"period":"1month","weight":-0.0536},{"period":"3month","weight":0.0206},{"period":"6month","weight":-0.02},{"period":"1year","weight":-0.0226},{"period":"ytd","weight":-0.0248}],"compareEarnings":[{"period":"1week","weight":-0.0117},{"period":"1month","weight":0.0007},{"period":"3month","weight":0.0025},{"period":"6month","weight":-0.0302},{"period":"1year","weight":0.1386},{"period":"ytd","weight":0.0069}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖北济川药业股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"32642人(较上一季度减少11.25%)","perCapita":"28142股","listingDate":"2001-08-22","address":"湖北省荆州市沙市区园林路时尚豪庭602室","registeredCapital":"92173万元","survey":" 湖北济川药业股份有限公司的主营业务是药品的研发、生产和销售。公司的主要产品是小儿豉翘清热颗粒、糖浆剂型、蒲地蓝消炎口服液、黄龙止咳颗粒、三拗片、健胃消食口服液、硫酸镁钠钾口服用浓溶液、甘海胃康胶囊、妇炎舒胶囊、蛋白琥珀酸铁口服溶液。2025年7月,“2024年度中国医药工业主营业务收入前100位企业”名单在第42届全国医药工业信息年会上发布,济川控股位列榜单第42位。","listedPrice":7.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供济川药业(600566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"济川药业,600566,济川药业股票,济川药业股票老虎,济川药业股票老虎国际,济川药业行情,济川药业股票行情,济川药业股价,济川药业股市,济川药业股票价格,济川药业股票交易,济川药业股票购买,济川药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"济川药业(600566)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供济川药业(600566)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}